
Emily Mesev
@EmilyMesev
Followers
175
Following
423
Media
9
Statuses
99
Medical writer specializing in autoimmune diseases and JAK inhibitors PhD in Molecular Biology from @Princeton tldr: innate immunity and JAK/STAT signaling🔬
Joined December 2020
So much type I & III interferon work to share! Take a look at two new papers from my PhD research if interferons or JAK/STAT signaling sound like a good time to you 😊 @PlossLab @toettch @PrincetonMolBio .
3
4
26
RT @scisignal: Why do type I #interferon receptors signal more strongly than type III receptors? The @PlossLab and @toettch lab find that t….
0
4
0
RT @scisignal: Preclinical experiments decipher how a protein promotes antibody responses through NF-kappaB signaling, scientists uncover t….
0
8
0
RT @PrincetonMolBio: Incoming viral attack🗡️! Interferon receptors to the defense🛡️, but what exactly is going on inside and outside the ce….
0
2
0
RT @toettch: And in an accompanying study, Emily used her synthetic receptors to uncover some interesting differences in JAK requirements f….
liebertpub.com
Type III interferons (IFN-λ) are central to host defense against viral infection of epithelial barrier surfaces. IFN-λ binding to its receptor induces a JAK-STAT cascade through kinases Janus-assoc...
0
1
0
RT @PlossLab: Please check out our newest study deciphering diff. in signaling strength betw type I&III #interferon receptors https://t.co/….
science.org
An intracellular motif in type I interferon receptors ensures they signal more strongly than their type III counterparts.
0
10
0
RT @h4rrymcnamara: hello world! new results (with @toettch): Stem cells can self-organize morphogenesis in vitro w….
0
89
0
Some super cool tool development by @PayamFarahani and @toettch!! Very glad I got to be part of this awesome project. Everyone should go read the reviewed paper!.
So happy to report that this has now been published in eLife (, where it might be one of the last stragglers under the "old" model there :). Thoroughly reviewed & extensively revised since the original preprint - see if you can spot the improvements! :).
0
0
2
RT @Yale: While both natural immunity and mRNA vaccines build protection against SARS-CoV-2, the vaccines side-step the development of self….
medicine.yale.edu
Yale researchers report that while both mRNA vaccines and SARS CoV-2 infection build immunity to the virus, they did not see new autoantibodies in those who
0
52
0
RT @prokuninaolsson: Here we are, the in-person part of the #IFNL22 meeting 🌴🌴🌴🤗! @CytokineSociety, @Lo_Zanzi, @drdeannasanter, @DrJuanLMen….
0
9
0
RT @PlossLab: Congratulations @EmilyMesev & thank you for presenting our joint work with @toettch at #cytokines2022 and #ilc4 #ifnl202….
0
2
0
RT @emperorliu1: Very excited that my work on the HBV genotypes is published @JHEP_Reports Many thanks to my mentor @PlossLab and everyone….
0
3
0
RT @EricTopol: Good graphic for how Omicron (and its various BA. family lineages) gets into cells, which differs from prior variants. A nic….
0
674
0
RT @rburdine1: Just an FYI - it costs you nothing to reference papers in your field in your own publications. It doesn't lessen the impact….
0
23
0
RT @PlossLab: New study reveals insights into how early immune response defines severity of COVID-19 .Congratulatio….
eurekalert.org
Two years into the COVID-19 pandemic, it is still unclear why some people infected with SARS-CoV-2 develop mild or no symptoms, while others develop severe disease. Researchers at Princeton Univers...
0
4
0
RT @coles_nicholas_: A year ago, a non-academic friend listened to a talk I gave. I thought it went great. My friend disagreed. She said t….
0
20K
0
RT @Drawrof1: I refuse to defend my thesis. It's never going to make it in this world if it doesn't learn to fight for itself.
0
763
0
RT @EricTopol: Ivermectin: the largest randomized, double-blind trial yet conducted, with early treatment, indicates there is no differenc….
0
6K
0